Ocriplasmin in the treatment of vitreomacular traction - for (original) (raw)

A retrospective study of a single practice use of ocriplasmin in the treatment of vitreomacular traction

Igor Kozak

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society, 2014

View PDFchevron_right

Initial experience with ocriplasmin in the treatment of vitreomacular traction

David Isaac

Arquivos Brasileiros de Oftalmologia, 2016

View PDFchevron_right

Visual Function Response To Ocriplasmin For The Treatment Of Vitreomacular Traction And Macular Hole

Benedicte Lescrauwaet

Value in Health, 2014

View PDFchevron_right

Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study

Benedicte Lescrauwaet

Investigative ophthalmology & visual science, 2017

View PDFchevron_right

Incomplete vitreomacular traction release using intravitreal ocriplasmin

Stephen Russell, James Folk

Case reports in ophthalmology

View PDFchevron_right

Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study

P. Carpineto

Journal of ophthalmology, 2016

View PDFchevron_right

Impact of Vitreoretinal Interface Architecture on Successful Vitreomacular Traction Resolution in Eyes Scheduled for Intravitreal Ocriplasmin Therapy

sara kazerounian

Retina, 2017

View PDFchevron_right

Vitreomacular traction quantitative cutoffs for the assessment of resolution after ocriplasmin intravitreal treatment

Luisa Pierro

Scientific Reports

View PDFchevron_right

Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study

Efstratios Parikakis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2015

View PDFchevron_right

Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes

Anselm Kampik

New England Journal of Medicine, 2012

View PDFchevron_right

Six months follow up of a single intravitreal injection of ocriplasmin for symptomatic vitreomacular adhesion

Elena Pacella

Senses and Sciences, 2016

View PDFchevron_right

Patient-reported outcomes of ocriplasmin for the treatment of vitreomacular traction: a systematic review and synthesis of the literature

Benedicte Lescrauwaet

Patient Related Outcome Measures

View PDFchevron_right

Initial Outcomes Following Intravitreal Ocriplasmin for Treatment of Symptomatic Vitreomacular Adhesion

Jaclyn Kovach, William Smiddy

Ophthalmic Surgery, Lasers and Imaging Retina, 2013

View PDFchevron_right

Association Between Anatomical Resolution and Functional Outcomes in the Mivi-Trust Studies Using Ocriplasmin to Treat Symptomatic Vitreomacular Adhesion/Vitreomacular Traction, Including When Associated with Macular Hole

Anselm Kampik

Retina, 2015

View PDFchevron_right

Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole

Benedicte Lescrauwaet

Journal of market access & health policy, 2016

View PDFchevron_right

Ocriplasmin for Vitreoretinal Diseases

Ehsan Rahimy

Journal of Biomedicine and Biotechnology, 2012

View PDFchevron_right

Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up

Francisco Gomez-ulla

Documenta Ophthalmologica, 2015

View PDFchevron_right

Ocriplasmin versus vitrectomy for the treatment of macular holes

David Chow

Canadian Journal of Ophthalmology, 2018

View PDFchevron_right

Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin

Iris Moroz

JAMA ophthalmology, 2014

View PDFchevron_right

Retinal breaks due to intravitreal ocriplasmin

Theodore Leng

Clinical Ophthalmology, 2014

View PDFchevron_right

The predictability of ocriplasmin treatment effects: is there consensus among retinal experts? Results from the EXPORT study

sara kazerounian

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017

View PDFchevron_right

Treatment Outcomes and Spectral-Domain Optical Coherence Tomography Findings of Eyes With Symptomatic Vitreomacular Adhesion Treated With Intravitreal Ocriplasmin

Auvni Patel

American Journal of Ophthalmology, 2015

View PDFchevron_right

Characterization of Vitreoretinal Interface Disorders Using OCT in the Interventional Phase 3 Trials of Ocriplasmin

Sandra Stinnett

Investigative Ophthalmology & Visual Science, 2012

View PDFchevron_right

Redesigning services for the management of vitreomacular traction and macular hole

W. Amoaku

Eye, 2014

View PDFchevron_right

Review of economic studies and budget impact analysis of ocriplasmin as a treatment of vitreomacular traction

Jeanette Pérez Ramos

Archivos de la Sociedad Espanola de Oftalmologia, 2016

View PDFchevron_right

Italian real-life experience on the use of ocriplasmin

Dario Pasquale Mucciolo

BMJ Open Ophthalmology

View PDFchevron_right

Microplasmin Intravitreal Administration in Patients with Vitreomacular Traction Scheduled for Vitrectomy

Marc Veckeneer, Anselm Kampik

Ophthalmology, 2009

View PDFchevron_right

Vitreomacular traction syndrome: a comparison of treatment with intravitreal plasmin enzyme vs spontaneous vitreous separation without treatment

Patrizia Della Valle

Eye, 2013

View PDFchevron_right

[Enzymatic vitrectomy by intravitreal autologous plasmin injection as initial treatment for macular epiretinal membranes and vitreomacular traction syndrome]

D. Salom

Archivos de la Sociedad Espanola de Oftalmologia

View PDFchevron_right

From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety

Ciro Costagliola

Expert Opinion on Drug Safety, 2016

View PDFchevron_right

Budget impact analysis of ocriplasmin for the treatment of symptomatic vitreomacular adhesion in the USA

Renée Arnold

Journal of Comparative Effectiveness Research, 2018

View PDFchevron_right

Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)

Kimberly Drenser

Clinical Ophthalmology, 2021

View PDFchevron_right

Pharmacokinetics of Ocriplasmin in Vitreous

Peter Stalmans, J. Van Calster

Investigative Ophthalmology & Visual Science, 2012

View PDFchevron_right